NCT05806606Completed
Effect and Cost Effectiveness of a Dyadic Empowerment-based Heart Failure Management Program for Self-care
The Effects and Cost-effectiveness of a Dyadic Empowerment-based Heart Failure Management Program (De-HF) on Self-care, HRQL and Hospital Readmission: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 31 Jul 2026
Brief summary (registry, in English)
Global population aging has drastically increased healthcare spending worldwide, with the greatest portion going to hospital and community health services. Heart failure (HF), as the final form of many cardiovascular diseases resulting from insufficient myocardial pumping. Ineffective self-care is consistently identified as the major modifiable risk factor for HF decompensation requiring hospitalization. It refers to an active cognitive process that influence patients' engagement in self-care maintenance, symptom perception and self-care management. However, current studies pay much focus on interventions such as motivational interviewing and behavioural activation to enhance the HF-related self-care and health outcomes which only produces short-term benefits. In fact, the lack of a sustainable effect from the self-care supportive interventions might be related the use of patient-centric design in these studies, which totally ignores the fact that HF management takes place in a dyadic context. To advance, active strategies were adopted to mobilize collaborative effort of the dyad in actual disease management. This study aims to evaluate the effects and cost-effectiveness of a Dyadic empowerment-based Heart Failure Management Program (De-HF) for self-care, health outcomes, and health service utilization among HF patients who require family support after hospital discharge. The De-HF program is based on the Theory of Dyadic Illness Management to enhance the congruence in illness perception and active dyadic collaboration in managing HF via both face-to-face and online platforms.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 232 (actual)
- First submitted
- 28 Mar 2023
- Start date
- 17 Apr 2023
- Primary completion date
- 1 Sept 2025
- Lead sponsor
- The University of Hong Kong
- Diseases
- Heart failure
- NCT number
- NCT05806606
What you commit to
- Study type: Interventional
- Participants enrolled: 232
- From 17 Apr 2023 to the primary completion date, 1 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- With end-stage renal disease relying on hemodialysis rather than HF medications to regulate fluid volume.
Other
- Not living with primary caregiver
Who the study is looking for
- Aged 18 or above
- Confirmed medical diagnosis of Heart Failure by a cardiologist of at least 3 months
- New York Heart Association (NYHA) Class II-IV symptoms
- Discharged home after an admission to the recruitment setting
- Carer co-residing with the patients in the same household
- Carer self-identified as the primary carer for the patients
- Both the patient and the carer having adequate cognitive ability (as indicated by an Abbreviated Test Score of \>6)
- Have at least one Smartphone or device to access the online meetings and videos
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Medicine, Tseung Kwan O Hospital Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.